Cabozantinib clinical trials
Also written Cabometyx, XL184, Cometriq and BMS-907351.
ClinicalTrials.gov finds 299 studies for cabozantinib. How that becomes 222 here
Every study that search finds has been read, apart from the 1 newest, to see whether and how it gives cabozantinib. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 299Found by its intervention search · See all 299 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 265 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −2
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)NCT06698250 · Mentioned only to compare zanzalintinibReport a problem
- The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM PatientsNCT07015021 · Named in error; carfilzomib is the drug givenReport a problem
- −1New since the last reading, not read yet
- 296Give cabozantinib to participants
- −27Observe patients on it, or give it outside a trial
- −1Use it as a tool: an imaging tracer or a test of drug response
- −7Compare another treatment with it
- −39Give it beside what is tested
- 222Test it: the count on this site
Get an email when these change. Save the cabozantinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 29 Nov 2012 · COMETRIQ · NDA 203756 (FDA, Drugs@FDA)
- European Union
- 21 Mar 2014 · Cometriq · EMEA/H/C/002640 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
222 studies that test it; most in 2020 (34)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 16 |
| 2013 | 18 |
| 2014 | 8 |
| 2015 | 7 |
| 2016 | 4 |
| 2017 | 10 |
| 2018 | 24 |
| 2019 | 18 |
| 2020 | 34 |
| 2021 | 21 |
| 2022 | 18 |
| 2023 | 13 |
| 2024 | 6 |
| 2025 | 5 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 36 · Other 186
National Cancer Institute (NCI) (33) · Exelixis (23) · M.D. Anderson Cancer Center (10) · Dana-Farber Cancer Institute (8) · Memorial Sloan Kettering Cancer Center (6) · Massachusetts General Hospital (6) · Bristol-Myers Squibb (5) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (5)
Often tested with
Tested in the same studies.
Nivolumab (36) · Ipilimumab (18) · Atezolizumab (15) · Pembrolizumab (11) · Lenvatinib (7) · Temozolomide (5) · Sunitinib (5) · Erlotinib (4)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 3 phase 3 studies under way
Cabozantinib is the comparator. A study of two new drugs counts under both.
- 1Belzutifan · Merck Sharp & Dohme LLC
- 1Selpercatinib · Loxo Oncology, Inc.
- 1Zanzalintinib · Merck Sharp & Dohme LLC · next primary completion Feb 2032
New treatments tested with it · 8 most studied
New when their studies opened, with cabozantinib beside them; studies of each.
Reaching primary completion within a year · 30
Studies that test cabozantinib.
- Nov 2026Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerPhase 2 · University of Utah
- Nov 2026Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate CancerPhase 2 · Rana McKay, MD
- Dec 2026Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerPhase 1 · University of Utah
- Dec 2026Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine TumorsPhase 2 · Fox Chase Cancer Center
- Dec 2026Cabozantinib for Patients With Recurrent or Progressive MeningiomaPhase 2 · Baptist Health South Florida
- Dec 2026Combination of Pembrolizumab and Cabozantinib in Patients With Advanced SarcomasPhase 2 · Institut Bergonié
- Dec 2026Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCPhase 2 · Bradley A. McGregor, MD
- Jan 2027BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyPhase 2 · National Cancer Institute (NCI)
- Jan 2027Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaPhase 2 · University of California, Irvine
- Feb 2027A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)Phase 1/2 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses cabozantinib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 222
- Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid CancerRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT06475989Against dabrafenib and trametinib in thyroid cancerWritten as CabozantinibReport a problem
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingPhase 2National Cancer Institute (NCI)NCT03866382With nivolumab and ipilimumab in rare genitourinary tumoursWritten as Cabozantinib S-malateReport a problem
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingPhase 2National Cancer Institute (NCI)NCT05136196With nivolumab in melanoma and skin cancerWritten as Cabozantinib S-malateReport a problem
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Continued in a rollover studyWritten as CabozantinibReport a problem
- Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL ActivityRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT01639508Alone in RET fusion-positive lung cancerWritten as CabozantinibReport a problem
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationPhase 3ExelixisNCT07620574Continued in an Exelixis extension studyWritten as CabozantinibReport a problem
- Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingPhase 2University of California, IrvineNCT04472767With nivolumab, ipilimumab and TACE in liver cancerWritten as CabozantinibReport a problem
- Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to RelapseRecruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT07871864Maintenance against supportive care in osteosarcomaWritten as Experimental group : Cabometyx ® 40mg/m2/day (Max: 60mg/day) , Treatment schedule : Daily**, day 1-28 during 4 weeks (ie. 1 cycle) during 12 cyclesReport a problem
- Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)RecruitingPhase 2University of Texas Southwestern Medical CenterNCT05931393Higher dose after earlier treatment in kidney cancerWritten as Cabozantinib 80 MGReport a problem
- A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)RecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT06835972With abemaciclib in kidney cancerWritten as CabozantinibReport a problem
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07405164Continued in a belzutifan extension studyWritten as CabozantinibReport a problem
- Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS StudyRecruitingPhase 2M.D. Anderson Cancer CenterNCT05019703With atezolizumab in adolescents and young adultsWritten as CabozantinibReport a problem
- Study of Cabozantinib With Selumetinib for Plexiform NeurofibromasRecruitingPhase 1Girish Dhall, MDNCT06502171With selumetinib in plexiform neurofibromasWritten as Cabozantinib Oral TabletReport a problem
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve OutcomesRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT07194044Added to sequential chemotherapy in Ewing sarcomaWritten as CabozantinibReport a problem
- A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesRecruitingPhase 2M.D. Anderson Cancer CenterNCT05048212With nivolumab and ipilimumab for kidney cancer brain metastasesWritten as CabozantinibReport a problem
- Cabozantinib With Ifosfamide in Relapsed/Refractory SarcomasRecruitingPhase 1Children's Hospital of PhiladelphiaNCT06156410With ifosfamide in sarcomasWritten as CabozantinibReport a problem
- Cabozantinib Dose Skipping as an Alternative to Dose ReductionsRecruitingPhase 2dr. Tom van der HulleNCT07077161Dose skipping against dose reductionsWritten as CabozantinibReport a problem
- Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC StudyRecruitingPhase 2Vanderbilt-Ingram Cancer CenterNCT05361720With nivolumab, chosen by tumour genetics in kidney cancerWritten as CabozantinibReport a problem
- Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1University of UtahNCT05613894With 177Lu-PSMA, doses escalatedWritten as CabozantinibReport a problem
- Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept StudyRecruitingPhase 1M.D. Anderson Cancer CenterNCT07187869Alone or with nivolumab; bone microenvironment studiedWritten as CabozantinibReport a problem
See all 222 studies that test cabozantinib →
Behind its US label · 6 — the studies the FDA label of CABOMETYX describes
From the Clinical Studies section of CABOMETYX (2025-10), as openFDA has it. A study the site does not hold is left out.
- Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney CancerCompletedPhase 2National Cancer Institute (NCI)NCT01835158Report a problem
- A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell CarcinomaCompletedPhase 3ExelixisNCT01865747Report a problem
- Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior SorafenibCompletedPhase 3ExelixisNCT01908426Report a problem
- A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaCompletedPhase 3Bristol-Myers SquibbNCT03141177Report a problem
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsActive, not recruitingPhase 3National Cancer Institute (NCI)NCT03375320Report a problem
- A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyActive, not recruitingPhase 3ExelixisNCT03690388Report a problem
Tested on its own · 98 — no other medicine in its arm
- Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid CancerRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT06475989Against dabrafenib and trametinib in thyroid cancerWritten as CabozantinibReport a problem
- Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL ActivityRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT01639508Alone in RET fusion-positive lung cancerWritten as CabozantinibReport a problem
- Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)RecruitingPhase 2University of Texas Southwestern Medical CenterNCT05931393Higher dose after earlier treatment in kidney cancerWritten as Cabozantinib 80 MGReport a problem
- Cabozantinib With Ifosfamide in Relapsed/Refractory SarcomasRecruitingPhase 1Children's Hospital of PhiladelphiaNCT06156410With ifosfamide in sarcomasWritten as CabozantinibReport a problem
- Cabozantinib Dose Skipping as an Alternative to Dose ReductionsRecruitingPhase 2dr. Tom van der HulleNCT07077161Dose skipping against dose reductionsWritten as CabozantinibReport a problem
- Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1University of UtahNCT05613894With 177Lu-PSMA, doses escalatedWritten as CabozantinibReport a problem
- Cabozantinib for Patients With Recurrent or Progressive MeningiomaRecruitingPhase 2Baptist Health South FloridaNCT05425004Alone in meningiomaWritten as CabozantinibReport a problem
- Cabozantinib to Treat Recurrent Liver Cancer Post TransplantRecruitingPhase 2University Health Network, TorontoNCT04204850Alone in liver cancer after transplantWritten as CabozantinibReport a problem
- Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination TherapyNot yet recruitingPhase 2National Health Research Institutes, TaiwanNCT07151326Alone after first-line immunotherapy combinations in liver cancerWritten as CabozantinibReport a problem
- A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid TumorsRecruitingPhase 2Nationwide Children's HospitalNCT05135975Maintenance in high-risk paediatric tumoursWritten as CabozantinibReport a problem
- A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and BevacizumabNot yet recruitingPhase 2Chulalongkorn UniversityNCT06535737Alone after atezolizumab-bevacizumab in liver cancerWritten as CabozantinibReport a problem
- Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied PatientsNot yet recruitingPhase 2Centre Hospitalier Universitaire de BesanconNCT05241561In patients on haemodialysisWritten as CabozantinibReport a problem
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsActive, not recruitingPhase 3National Cancer Institute (NCI)NCT03375320On the US labelAgainst placebo in neuroendocrine tumoursWritten as Cabozantinib S-malateReport a problem
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02867592In children with sarcomas and rare tumoursWritten as CabozantinibReport a problem
- Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With OsteosarcomaTerminatedPhase 2IpsenNCT06341712Maintenance against supportive care in osteosarcomaWritten as CabozantinibReport a problem
- Cabozantinib in High Grade Neuroendocrine NeoplasmsActive, not recruitingPhase 2Washington University School of MedicineNCT04412629Alone in high-grade neuroendocrine tumoursWritten as CabozantinibReport a problem
- A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid CancerActive, not recruitingPhase 4ExelixisNCT01896479Two doses in medullary thyroid cancerWritten as Cabozantinib (XL184) 140 mgReport a problem
- A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyActive, not recruitingPhase 3ExelixisNCT03690388On the US labelAgainst placebo in radioiodine-refractory thyroid cancerWritten as CabozantinibReport a problem
- A Phase II Trial of Cabozantinib With Patients With Refractory GCTsCompletedPhase 2Jennifer KingNCT04876456Alone in germ cell tumoursWritten as CabozantinibReport a problem
- Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint InhibitorsCompletedPhase 2IpsenNCT03945773Second line after checkpoint drugs in kidney cancerWritten as CabozantinibReport a problem
Showing 20 of 98. See all 98 →
Tested with established drugs · 21 — they are given beside it
- Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to RelapseRecruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT07871864Maintenance against supportive care in osteosarcomaWritten as Experimental group : Cabometyx ® 40mg/m2/day (Max: 60mg/day) , Treatment schedule : Daily**, day 1-28 during 4 weeks (ie. 1 cycle) during 12 cyclesReport a problem
- Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept StudyRecruitingPhase 1M.D. Anderson Cancer CenterNCT07187869Alone or with nivolumab; bone microenvironment studiedWritten as CabozantinibReport a problem
- Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine TumorsRecruitingPhase 2Fox Chase Cancer CenterNCT05263050An alternative dose schedule, alone or with nivolumabWritten as CabozantinibReport a problem
- Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CancerRecruitingPhase 1Emory UniversityNCT04878029With enfortumab vedotin in urothelial cancerWritten as Cabozantinib S-malateReport a problem
- Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After SurgeryActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05111574Added to nivolumab after mucosal melanoma surgeryWritten as Cabozantinib S-malateReport a problem
- Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyActive, not recruitingPhase 3National Cancer Institute (NCI)NCT03793166Added to nivolumab after induction in kidney cancerWritten as CabozantinibReport a problem
- Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV StudyActive, not recruitingPhase 3National Cancer Institute (NCI)NCT05092958Added to avelumab maintenance in bladder cancerWritten as Cabozantinib S-malateReport a problem
- Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal CancerSuspendedPhase 2National Cancer Institute (NCI)NCT05904080Added to nivolumab and ipilimumabWritten as Cabozantinib S-malateReport a problem
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed OsteosarcomaSuspendedPhase 2/3National Cancer Institute (NCI)NCT05691478Added to chemotherapy in osteosarcomaWritten as Cabozantinib S-malateReport a problem
- Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaActive, not recruitingPhase 3ExelixisNCT03937219Added to nivolumab and ipilimumab in kidney cancerWritten as CabozantinibReport a problem
- Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue SarcomaActive, not recruitingPhase 2National Cancer Institute LAONCT05836571Added to nivolumab and ipilimumabWritten as CabozantinibReport a problem
- Cabozantinib and Pembrolizumab for Advanced Metastatic MelanomaTerminatedPhase 1/2John RiethNCT03957551With pembrolizumab in melanomaWritten as CabozantinibReport a problem
- A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1/2ExelixisNCT00596648Alone or with erlotinib in lung cancerWritten as XL184Report a problem
- Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPCTerminatedPhase 2ExelixisNCT01995058With abiraterone in prostate cancerWritten as cabozantinibReport a problem
- Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast CancerCompletedPhase 2Massachusetts General HospitalNCT01441947Alone or with fulvestrant in breast cancerWritten as CabozantinibReport a problem
- Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell CarcinomaCompletedPhase 1/2University of Colorado, DenverNCT03149822With pembrolizumab in kidney cancerWritten as CabozantinibReport a problem
- XL-184+Abiraterone in Post-Chemo CRPCCompletedPhase 1Dana-Farber Cancer InstituteNCT01574937With abiraterone after chemotherapy in prostate cancerWritten as CabozantinibReport a problem
- Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain MetastasesCompletedPhase 2Dana-Farber Cancer InstituteNCT02260531Alone or with trastuzumab in breast cancer brain metastasesWritten as CabozantinibReport a problem
- Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal CancerCompletedPhase 1John Strickler, M.D.NCT02008383Alone or with panitumumab in colorectal cancerWritten as CabozantinibReport a problem
- Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT01683994Added to docetaxel and prednisone in prostate cancerWritten as CabozantinibReport a problem
Showing 20 of 21. See all 21 →
Tested in a combination · 103 — another drug in the study is under test too
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingPhase 2National Cancer Institute (NCI)NCT03866382With nivolumab and ipilimumab in rare genitourinary tumoursWritten as Cabozantinib S-malateReport a problem
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingPhase 2National Cancer Institute (NCI)NCT05136196With nivolumab in melanoma and skin cancerWritten as Cabozantinib S-malateReport a problem
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Continued in a rollover studyWritten as CabozantinibReport a problem
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationPhase 3ExelixisNCT07620574Continued in an Exelixis extension studyWritten as CabozantinibReport a problem
- Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingPhase 2University of California, IrvineNCT04472767With nivolumab, ipilimumab and TACE in liver cancerWritten as CabozantinibReport a problem
- A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)RecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT06835972With abemaciclib in kidney cancerWritten as CabozantinibReport a problem
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07405164Continued in a belzutifan extension studyWritten as CabozantinibReport a problem
- Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS StudyRecruitingPhase 2M.D. Anderson Cancer CenterNCT05019703With atezolizumab in adolescents and young adultsWritten as CabozantinibReport a problem
- Study of Cabozantinib With Selumetinib for Plexiform NeurofibromasRecruitingPhase 1Girish Dhall, MDNCT06502171With selumetinib in plexiform neurofibromasWritten as Cabozantinib Oral TabletReport a problem
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve OutcomesRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT07194044Added to sequential chemotherapy in Ewing sarcomaWritten as CabozantinibReport a problem
- A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesRecruitingPhase 2M.D. Anderson Cancer CenterNCT05048212With nivolumab and ipilimumab for kidney cancer brain metastasesWritten as CabozantinibReport a problem
- Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC StudyRecruitingPhase 2Vanderbilt-Ingram Cancer CenterNCT05361720With nivolumab, chosen by tumour genetics in kidney cancerWritten as CabozantinibReport a problem
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingPhase 2Centre Leon BerardNCT04116541Alone in one matched armWritten as CabozantinibReport a problem
- Cabozantinib and Dostarlimab in Recurrent Gynecologic CarcinosarcomaRecruitingPhase 1/2University of Alabama at BirminghamNCT05559879With dostarlimab in carcinosarcomaReport a problem
- Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine TumorsRecruitingPhase 1/2National Health Research Institutes, TaiwanNCT05048901With lanreotide in neuroendocrine tumoursWritten as CabozantinibReport a problem
- Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical CancerRecruitingPhase 2Emory UniversityNCT06006013With pembrolizumabWritten as Cabozantinib S-malateReport a problem
- Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal MalignanciesRecruitingPhase 1/2Anwaar SaeedNCT03539822With durvalumab, with or without tremelimumab, in GI cancersWritten as CabozantinibReport a problem
- A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingPhase 2University of Illinois at ChicagoNCT05613413With pembrolizumab as maintenance in squamous lung cancerWritten as CabozantinibReport a problem
- Combination of Pembrolizumab and Cabozantinib in Patients With Advanced SarcomasRecruitingPhase 2Institut BergoniéNCT05182164With pembrolizumab in sarcomasReport a problem
- Cabozantinib and Nivolumab Among Older Patients With Renal Cell CarcinomaRecruitingPhase 4Gustave Roussy, Cancer Campus, Grand ParisNCT06934057With nivolumab in older people with kidney cancerWritten as CabozantinibReport a problem
Showing 20 of 103. See all 103 →
Beside an established treatment under test · 11 — an approved drug, surgery or radiation is what the study tests
Tested with cabozantinib: Surgery or a procedure 7 · Radiation 4 · atezolizumab 3 · Ipilimumab 1 · Nivolumab 1 · Albumin-Bound Paclitaxel 1 · Acarbose 1
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingPhase 1National Cancer Institute (NCI)NCT03816345One standard option in people with autoimmune diseaseWritten as CabozantinibReport a problem
- Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06900595In every armBoth arms take it; cemiplimab is addedWritten as CabozantinibReport a problem
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingPhase 2NRG OncologyNCT05327686In every armA standard option; SABR is addedWritten as CabozantinibReport a problem
- Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver CancerRecruitingPhase 2Academic and Community Cancer Research UnitedNCT05168163In every armControl backbone; atezolizumab is addedWritten as CabozantinibReport a problem
- Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxRecruitingPhase 1M.D. Anderson Cancer CenterNCT05092373Partner of tumour treating fields in one cohortWritten as Cabozantinib S-malateReport a problem
- Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)RecruitingPhase 3Sun Yat-sen UniversityNCT06726421A standard option; SBRT is addedReport a problem
- Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.RecruitingPhase 4Fondazione Policlinico Universitario Agostino Gemelli IRCCSNCT06903312A standard option; tumour ablation is addedReport a problem
- Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 TrialActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05411081In every armBoth arms take it; atezolizumab is addedWritten as Cabozantinib S-malateReport a problem
- Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL StudyActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04071223In every armBoth arms take it; radium-223 is addedWritten as Cabozantinib S-malateReport a problem
- A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor TreatmentTerminatedPhase 3Hoffmann-La RocheNCT04338269In every armBoth arms take it; atezolizumab is addedWritten as CabozantinibReport a problem
- Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)WithdrawnPhase 2University of Alabama at BirminghamNCT05487859A standard option in one regimen; acarbose is addedReport a problem
Beside a new treatment under test · 20 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with cabozantinib: clostridium butyricum miyairi 588 strain 2 · CB-839 2 · casdatifan 2 · belzutifan 1 · PT2385 1 · pamiparib 1 · BMS-986527 1 · sapanisertib 1
- A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsRecruitingPhase 1Arcus Biosciences, Inc.NCT05536141Partner of new casdatifan in one cohortWritten as CabozantinibReport a problem
- Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT05663710In every armPartner of new 177Lu girentuximab with nivolumabWritten as CabozantinibReport a problem
- Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaRecruitingPhase 3Arcus Biosciences, Inc.NCT07011719In every armBoth arms take it; new casdatifan is addedWritten as CabozantinibReport a problem
- Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE TrialRecruitingPhase 1/2National Cancer Institute (NCI)NCT06811116In every armBoth arms take it; sapanisertib is addedWritten as Cabozantinib S-malateReport a problem
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)RecruitingPhase 1/2Bristol-Myers SquibbNCT07293351Partner of new pumitamigWritten as CabozantinibReport a problem
- KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsRecruitingPhase 1Kura Oncology, Inc.NCT06026410Partner of new darlifarnib in one armWritten as CabozantinibReport a problem
- A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)Not yet recruitingPhase 1Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT07848295Partner of new BMS-986527Written as CabozantinibReport a problem
- Autologous Dendritic Cell Vaccine in Kidney CancerRecruitingPhase 2Jodi MaranchieNCT05127824In every armGiven beside a new dendritic cell vaccineWritten as CabozantinibReport a problem
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerRecruitingPhase 3SWOG Cancer Research NetworkNCT07383441In every armA standard option; CBM588 is addedWritten as CabozantinibReport a problem
- A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular CarcinomaRecruitingPhase 1/2Iterion TherapeuticsNCT05797805Partner option for new tegavivintWritten as CabozantinibReport a problem
- Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid TumorsCompletedPhase 1M.D. Anderson Cancer CenterNCT05038839In every armPartner of new pamiparibWritten as CabozantinibReport a problem
- Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal CancersCompletedPhase 1Novartis PharmaceuticalsNCT03798626Standard partner; new gevokizumab is addedWritten as CabozantinibReport a problem
- CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerActive, not recruitingPhase 1City of Hope Medical CenterNCT05122546In every armBoth arms take it with nivolumab; CBM588 is addedWritten as Cabozantinib S-malateReport a problem
- A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell CarcinomaTerminatedPhase 1/2Genenta ScienceNCT06716853Partner of new Temferon gene therapyWritten as CabozantinibReport a problem
- A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)Active, not recruitingPhase 2Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT03634540In every armPartner of new belzutifanWritten as CabozantinibReport a problem
- A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)Active, not recruitingPhase 1Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02293980Partner of new PT2385 in one partWritten as CabozantinibReport a problem
- A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has SpreadCompletedPhase 1Bristol-Myers SquibbNCT04540705One TKI partner of new bempegaldesleukin with nivolumabWritten as CabozantinibReport a problem
- Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell CarcinomaTerminatedPhase 1/2Aravive, Inc.NCT04300140Partner of new batiraxceptWritten as Cabozantinib (Cabo)Report a problem
- CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell CarcinomaCompletedPhase 2Calithera Biosciences, IncNCT03428217In every armBoth arms take it; new CB-839 is addedWritten as CabozantinibReport a problem
- Study of the Glutaminase Inhibitor CB-839 in Solid TumorsCompletedPhase 1Calithera Biosciences, IncNCT02071862Partner of new CB-839 in one armReport a problem
Beside supportive care · 6 — a supportive treatment or test is studied
- Intensified Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Management in Patients With Renal Cell CarcinomaRecruitingNot applicableCentro di Riferimento Oncologico - AvianoNCT07805122Given as treatment; drug monitoring for toxicity is studiedReport a problem
- TARGETed Therapy Drug MONITOring in DIGestive OncologyRecruitingNot applicableUNICANCERNCT05443087Given as treatment; drug monitoring is studiedReport a problem
- Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal CarcinomaRecruitingPhase 4Centre Francois BaclesseNCT07028125Every patient takes it with nivolumab; digital monitoring is testedReport a problem
- Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney CancerRecruitingNot applicableInstitut du Cancer de Montpellier - Val d'AurelleNCT04823923Given as treatment; drug levels in kidney failure studiedReport a problem
- Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.CompletedPhase 2Fudan UniversityNCT05673824One TKI option; Huaier granule is tested for kidney effectsReport a problem
- Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal CancerTerminatedNot applicableDuke UniversityNCT03867045Given as treatment; a symptom management app is developedReport a problem
One option of several · 2 — a test or a strategy chooses among drugs
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524In every armOne of many drugs in individualised combinationsWritten as CabozantinibReport a problem
- High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute LeukemiaCompletedNot applicableUniversity of WashingtonNCT02551718One drug a sensitivity assay can chooseReport a problem
As the comparator · 7 — what is tested is compared with cabozantinib
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05773274One comparator option against 177Lu-DOTATATE retreatmentWritten as CabozantinibReport a problem
- A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07227402The comparator for belzutifan with zanzalintinibWritten as CabozantinibReport a problem
- A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT04586231The comparator for belzutifan with lenvatinibWritten as CabozantinibReport a problem
- Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT05012371The comparator for lenvatinib with everolimusWritten as CabozantinibReport a problem
- A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid CancerActive, not recruitingPhase 3Loxo Oncology, Inc.NCT04211337One comparator option against selpercatinibWritten as CabozantinibReport a problem
- A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).WithdrawnPhase 3Hoffmann-La RocheNCT04760288One comparator option against pralsetinibWritten as CabozantinibReport a problem
- A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)TerminatedPhase 3Nektar TherapeuticsNCT03729245One comparator option against new bempegaldesleukinWritten as cabozantinibReport a problem
Observed · 27 — patients on it are followed, or it is given outside a trial
- A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) PatientsRecruitingNovartis PharmaceuticalsNCT07635316One treatment in neuroendocrine tumour practiceReport a problem
- Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior TreatmentRecruitingIpsenNCT07314164Real-life use in neuroendocrine tumoursReport a problem
- TDM for Optimized Outcome in Patients With mRCC.RecruitingNiels FristrupNCT04659343Drug levels measured during treatmentReport a problem
- International Multicentric Study ARON-1RecruitingHospital of MacerataNCT05287464One kidney cancer combination in a registryReport a problem
- Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinibRecruitingGruppo Oncologico Italiano di Ricerca ClinicaNCT06548867Retrospective use in kidney cancerWritten as CabozantinibReport a problem
- First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in SpainActive, not recruitingBristol-Myers SquibbNCT07852884One first-line option in Spanish kidney cancer recordsReport a problem
- Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)Active, not recruitingIpsenNCT04106349Alone or with nivolumab in practiceReport a problem
- Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.Active, not recruitingIpsenNCT03647878Alone or with nivolumab in practiceReport a problem
- A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in AdultsCompletedIpsenNCT05361434With nivolumab first-line in practiceReport a problem
- Cabozantinib in the Elderly With Metastatic Renal Cell CarcinomaCompletedIstituto Oncologico Veneto IRCCSNCT04416646Use in older people with kidney cancerWritten as CabozantinibReport a problem
- Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular CarcinomaCompletedTakedaNCT05100082Post-marketing survey in liver cancerWritten as CabozantinibReport a problem
- Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination ImmunotherapyCompletedH. Lee Moffitt Cancer Center and Research InstituteNCT05579847Patients on it use an educational appReport a problem
- Survey of Cabozantinib Used To Treat People With Renal Cell CarcinomaCompletedTakedaNCT04804813Post-marketing survey in kidney cancerWritten as CabozantinibReport a problem
- Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing CombinationCompletedIpsenNCT04957160After first-line checkpoint combinations, observedReport a problem
- A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.CompletedPfizerNCT05363072One treatment in a kidney cancer populationReport a problem
- A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.CompletedIpsenNCT05444933Second-line use in France, retrospectiveReport a problem
- CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional StudyTerminatedInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT04147143After earlier treatment in kidney cancer, observedReport a problem
- Spanish Real-World Evidence CabozantinibCompletedSpanish Oncology Genito-Urinary GroupNCT04510688Real-world use in SpainWritten as CabozantinibReport a problem
- Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell CarcinomaCompletedIpsenNCT03419572Real-world use in kidney cancerReport a problem
- BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer)Status unknownCentre Leon BerardNCT03628859One treatment option; biomarkers of response observedReport a problem
Showing 20 of 27. See all 27 →
As a tool · 1 — an imaging tracer or a test of drug response
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
- Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With OsteosarcomaOct 29, 2026NCT06341712
Codes
What other systems call cabozantinib · ClinicalTrials.gg INT005839
- MeSH (NLM) C558660cabozantinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 1C39JW444GCABOZANTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1363268Confirmed FDA, Wikidata
- Wikidata Q795057cabozantinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C52200CabozantinibOne source FDA
- DrugBank DB08875One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C558660 | cabozantinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 1C39JW444G | CABOZANTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1363268 | — | Confirmed FDA, Wikidata |
| Wikidata | Q795057 | cabozantinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C52200 | Cabozantinib | One source FDA |
| DrugBank | DB08875 | — | One source Wikidata |
Also registered as cabozantinib s-malate (UNII DR7ST46X58 · RxNorm 1363267).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.